What is the dividend growth rate of CSL stock?

CSL's dividends are worth more than what meets the eye.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) may be the third-largest stock on the S&P/ASX 200 Index (ASX: XJO). But unlike most of its peers in the top echelons of the ASX 200, CSL is not well-known as a generous dividend payer. 

In fact, out of the ASX 200's top ten shares, CSL is currently one of only two shares that today offers a dividend yield of under 3% (the other being Goodman Group (ASX: GMG)).

However, this simple observation hides what has been a fairly compelling dividend growth story for CSL shares and their owners. So today, let's dive into the dividend growth history of the CSL share price.

Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

What is a dividend growth rate?

A dividend growth rate simply refers to the consistency and magnitude of a company's dividend growth over time. If a company pays out $1 per share in dividends in one year, but $1.10 in the next and $1.20 in the year after that, we can say it has an average dividend growth rate of 10% per annum.

Of course, many companies don't consistently grow their dividend every single year. Many, particularly cyclical shares like mining companies, adjust them from year to year based on how much profits they are raking in.

Fortunately for lovers of consistently rising dividends, CSL shares fall into the former category.

What is the growth rate of the CSL dividend?

CSL shares have raised their shareholder income every single year since 2015, bar one. Back in 2015, shareholders enjoyed an annual total of US$1.24 per share. But by 2023, this had risen to US$2.36 per share.

That's following an annual dividend pay rise every single year except 2022. That year, investors enjoyed the same US$2.22 per share that they did in 2021.

Here's what that looks like in visual form:

CSL dividend growthrate
Chart: Author's Own

Over the eight years from 2015 to 2023, CSL's annual dividend rose from US$1.24 per share to US$2.36. This works out to represent an average compounded annual growth rate, and thus dividend growth rate, of 8.38%.

Not something you might assume when looking at the current CSL share price's trailing dividend yield of 1.21%.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goodman Group. The Motley Fool Australia has recommended CSL and Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

ASX share investor sitting with a laptop on a desk, pondering something.
Share Fallers

CSL shares crash to a 9-year low. Is it time to sell off my shares?

What's next for the beaten-down ASX biotech stock?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

This ASX biotech hit a 90% success rate. Can it unlock commercial growth?

Orthocell is already seeing growing adoption, with more than 300 surgeons across over 220 hospitals in Australia using Remplir.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

This ASX biotech is pushing for a Nasdaq listing. Could it reignite investor interest?

The NASDAQ has a reputation for providing a platform for some of the world's most innovative companies.

Read more »

Smiling health care workers in a medical setting.
Healthcare Shares

3 ASX healthcare shares to buy amid sector rout: experts

Healthcare shares have tumbled 36% over the past year amid multiple headwinds for the sector.

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech has just announced a major US deal

This company's heart disease technology is gaining traction.

Read more »

Devastated woman sits near smartphone on home kitchen floor troubled with loneliness.
Healthcare Shares

Which beaten down ASX healthcare stock is a better buy right now: Pro Medicus vs Cochlear shares

Which do experts prefer?

Read more »

Health professional working on his laptop.
Healthcare Shares

Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket

This broker sees big upside for this healthcare stock.

Read more »